Loading company…
Peptris uses machine learning to discover drug candidates for cancer, inflammation, and rare diseases.
Founded in 2019 and based in Bangalore, Peptris develops therapeutic programs using biotechnology and artificial intelligence. Its machine learning platform predicts small-molecule and protein interactions and supports drug discovery in oncology, inflammation, and rare diseases. In February 2026, the company raised INR 700 million in Series A funding from Indian Angel Network, Speciale Invest, Tenacity Ventures, and BYT Capital to advance programs toward clinical readiness and expand its pipeline.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in